University College London

University College London (UCL), headquartered in London, United Kingdom, operates as a prime recipient of federal grants and purchase orders across biomedical and defense research domains. The institution is a not-for-profit educational organization and state-controlled institution of higher learning with no SBA certifications; it competes on full-and-open basis across federal funding streams and does not pursue set-aside categories.

UCL's federal footprint centers on NIH-funded research in neurodegenerative disease, behavioral science, oncology, and infectious disease, alongside defense research partnerships with the Department of the Air Force. The institution acts as prime recipient on 121 of 213 total awards (57%) and subcontractor on 92 awards (43%), positioning it as a major research collaborator within the NIH ecosystem and defense research enterprise. Recent representative prime grants include a project grant on systems genetics analysis of resilience to tauopathy in Alzheimer's disease-related dementias (National Institute on Aging, awarded January 2025, running through December 2029), a cooperative agreement on advancing prevention research in cancer through ontology tools / APRICOT project (NIH Office of the Director, awarded September 2024, running through August 2029), and an artificial-intelligence-based radiotherapy treatment planning study (National Cancer Institute cooperative agreement, awarded September 2022, running through August 2027). Prime contract work includes a $345,500 purchase order from the National Institute on Drug Abuse for unspecified biomedical research support (awarded January 2024, completing October 2026) and a $48,500 purchase order from the National Institute of Mental Health for tuition payments supporting up to four doctoral students in the NIMH-UCL Doctoral Program (awarded September 2026, completing August 2027).

The top five customer agencies by award count account for approximately 52% of recent awards. The National Institute on Aging dominates volume with 36 awards; the Department of the Air Force follows with 23 awards; the National Institute on Drug Abuse carries 20 awards worth $2.2 million combined potential value; the National Institute of Neurological Disorders and Stroke holds 17 awards; and the National Institute of Allergy and Infectious Diseases carries 14 awards. By potential-value ranking, the National Institute on Drug Abuse leads at $2.2 million across 20 awards, followed by the National Institute of Mental Health at $49 thousand across 4 awards and the National Institute of Cancer at $20 thousand across 4 awards. The remainder of the portfolio is dominated by high-award-count, lower-dollar NIH institutes (particularly NIA with 36 awards and minimal disclosed potential value) and Air Force research grants. This divergence signals that UCL's volume is anchored to NIH research partnerships, many carrying below-threshold potential-value reporting, while the dollars visible in the source cluster in smaller NIMH and NIDA programs.

UCL participates in one named parent vehicle: an indefinite delivery contract (HHSN263200500027I) with one task order carrying $123 thousand in combined potential value. The institution does not hold seats on GWACs or government-wide IDIQs; its prime work routes through direct agency purchase orders and cooperative agreements rather than through multi-award vehicles.

Activity has grown year over year from seven awards in 2022 to forty-two in 2024, with eighteen awards in 2025 and four in 2026 (reflecting a partial-year reporting window). Three awards carrying combined potential value of $394 thousand reach ultimate completion within the next twenty-four months and face recompete exposure. SCI-reported service-contract activity is minimal—one subcontractor record in FY2025 accounting for 1.8 FTEs—reflecting the dominance of grant and research contract work over reportable service engagements.

In its subcontractor role, UCL operates as a research collaborator and performance site on multiple NIH-funded cooperative agreements and research programs. Named prime grantees include Vanderbilt University Medical Center (on discovery and characterization of rare variant effects in dilated cardiomyopathy biobank analysis, with multiple sub-awards in 2025–2026), Washington University (on the Dominantly Inherited Alzheimer Network performance site and DIAN-TU tau drug development phase 1b trials, with clinical and trial-design leadership from Dr. Ross Paterson at UCL's Dementia Research Centre), the Rockefeller University (on light beads microscopy neural recording technology, with UCL's Carandini/Harris laboratory providing analysis and implementation), The General Hospital Corporation (on HiP-CT brain imaging, with UCL/ESRF responsible for whole-brain imaging optimization and analysis), and Stanford University (on amyotrophic lateral sclerosis/frontotemporal dementia RNA biology and biomarker development). Across the sub-award footprint, UCL typically contributes specialized research expertise in neurodegenerative disease, advanced imaging, genetic analysis, and clinical trial oversight rather than serving as a general subcontractor.

UCL's capability portfolio centers on neuroscience research, particularly Alzheimer's disease and tau pathology, functional neurology, genetic and epidemiological analysis, behavioral science interventions, cancer prevention and treatment modeling, and advanced brain imaging (including high-resolution phase-space contrast-transfer and diffusion-weighted imaging analysis). The institution houses specialized research institutes including the Queen Square Institute of Neurology, the Dementia Research Centre, and the Blizard Institute, which anchor deep subject-matter expertise in neurodegeneration and clinical research. Category concentration shows colleges and universities (twelve awards) as the dominant NAICS classification, with education/training tuition payments and professional support services (eleven awards each) as the leading PSC categories.

The institution maintains a subsidiary, UCL Consultants LTD, which may house applied research and consulting delivery, though the source does not detail its operational scope or role within the prime award footprint.